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Background: Exome sequencing using next-generation sequencing technologies is a cost efficient approach to
selectively sequencing coding regions of human genome for detection of disease variants. A significant amount of
DNA fragments from the capture process fall outside target regions, and sequence data for positions outside target
regions have been mostly ignored after alignment.
Result: We performed whole exome sequencing on 22 subjects using Agilent SureSelect capture reagent and 6
subjects using Illumina TrueSeq capture reagent. We also downloaded sequencing data for 6 subjects from the
1000 Genomes Project Pilot 3 study. Using these data, we examined the quality of SNPs detected outside target
regions by computing consistency rate with genotypes obtained from SNP chips or the Hapmap database,
transition-transversion (Ti/Tv) ratio, and percentage of SNPs inside dbSNP. For all three platforms, we obtained
high-quality SNPs outside target regions, and some far from target regions. In our Agilent SureSelect data, we
obtained 84,049 high-quality SNPs outside target regions compared to 65,231 SNPs inside target regions (a 129%
increase). For our Illumina TrueSeq data, we obtained 222,171 high-quality SNPs outside target regions compared to
95,818 SNPs inside target regions (a 232% increase). For the data from the 1000 Genomes Project, we obtained
7,139 high-quality SNPs outside target regions compared to 1,548 SNPs inside target regions (a 461% increase).
Conclusions: These results demonstrate that a significant amount of high quality genotypes outside target regions
can be obtained from exome sequencing data. These data should not be ignored in genetic epidemiology studies.
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Next-generation sequencing technologies have substan-
tially decreased the cost of sequencing large genomic
regions. It is still financially prohibitive, however, to per-
form whole genome sequencing for a large number of
subjects, especially for large scale genetic epidemiology
association studies, at a sufficient depth for accurate
genotype calls. The exome represents about 1% of the
human genome with approximately 30 million base pairs
[1] but accounts for over 85% of all mutations identified
in Mendelian disorders [2]. As a result, exome sequen-
cing is currently an attractive and practical approach for
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reproduction in any medium, provided the orWhile exome sequencing primarily targets exons, non-
coding regions such as introns, intron-exon boundary
regions, UTRs, and intergenic regions can also be
sequenced as a byproduct. It is well known that SNPs
located in promoter and UTR regions may regulate gene
expression. It was traditionally believed that introns were
not as important as exons, but many studies have now
established some functional significance for introns. For
example, Rearick et al. [3] suggested that some introns
can encode specific proteins and can be processed after
splicing to form noncoding RNA molecules. Yi et al. [4]
found a pair of intronic SNPs from the EPAS1 gene that
show strongly elevated allele frequencies in Tibetans
compared with Han Chinese. Furthermore, intergenic
regions comprise around 70% of the human genome.
Many GWAS have established strong associations be-
tween intergenic SNPs and diseases [5-7], and many of
the results have been replicated in independent data-
sets. Based on the results from the 1000 Genomes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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plex traits identified by GWAS (www.genome.gov/gwas-
tudies), under 30% are either annotated as a non-
synonymous variant or in substantial LD (r2 ≥ 0.5) with a
non-synonymous variant.
Exome and targeted sequencing requires capture of
DNA fragments that overlap with target regions. Al-
though a captured library is greatly enriched for target
regions, a significant fraction of DNA fragments still fall
outside target regions. The fraction varies depending on
capture efficiency. For example, Yi et al. [4] (using Nim-
bleGen 2.1 M kit) reported having 64.5% of sequenced
bases outside target regions and 31.9% more than 500 bp
away from target regions; Ng et al. [2] (using Agilent
244 K microarrays for target enrichment) reported over
50% of sequenced bases outside target regions. Our data
obtained with Agilent SureSelect v1 capture kit also had
nearly 50% of sequenced bases outside target regions. As
a result, a significant fraction of intronic and intergenic
regions may have been sequenced, which may include
promoters, conserved non-coding sequences, untrans-
lated regions, miRNA sites, and other potentially func-
tional regions. It has been a common practice to ignore
data outside target regions and focus only on the bases
inside target regions [2,4,9-11]. While justified, this ap-
proach is inefficient as it overlooks a large amount of
data that would otherwise be useful in genetics studies.
In this paper, we systematically evaluate the quality of
data outside target regions using our exome sequencing
data and a subset of the Pilot 3 data from the 1000 Gen-
omes Project [12]. The Agilent SureSelect v1 capture kit
(38 million bases) and Illumina TrueSeq capture kit (62
million bases) used in our exome study are two of the
most widely used kits for exome sequencing studies. The
1000 Genomes Project Pilot 3 data focused on the exons
of a thousand randomly selected genes as target regions
and used Agilent's array enrichment method (2.1 million
bases) [8]. For both our data and the data from the 1000
Genomes Project, we will describe coverage, data quality,




We studied whole exome sequencing data for 28 breast
cancer patients recruited to the Shanghai Breast Cancer
Study (SBCS). The SBCS is a large, population-based
case–control study of women in urban Shanghai, the
details of which have been previously described [13]. All
patients had very early-onset (22–32 years old) breast
cancer or early-onset (38–41 years old) plus first-degree
family history of breast cancer. Genomic DNA from
buffy coat was extracted using QIAmp DNA kit (Qiagen,
Valencia, CA) following the manufacture’s protocol.Approval of the study was granted by the relevant insti-
tutional review boards in both China and the United
States. All of our samples have been genotyped using the
Affymetrix 6.0 array in a previous genome wide associ-
ation study [13].
We studied 22 exomes captured using the Agilent Sur-
eSelect kit and 6 exomes captured using the Illumina
TrueSeq kit. Our Agilent SureSelect exome data were
72-base paired-end reads generated from Illumina GA
IIx machines. Each sample was run on a single lane of a
flowcell. DNA enrichment was done using Agilent Sure-
Select Human All Exon kit v1 which was designed to
target 165,637 genomic regions (37.8 million bases;
71.6% inside exons; average length 228 bp). Our Illumina
TrueSeq exome data were 100-base paired-end reads.
The six samples were barcoded and sequenced on Illu-
mina HiSeq2000 (five samples per lane). The TrueSeq
capture kit targets 201,071 regions (62.1 million bases;
49.3% inside exons; average length 309 bp). The consen-
sus coding sequences database (CCDS) [14] has 27.8
million bases, 98.3% of which are covered by the SureSe-
lect target regions and 96.5% by the TrueSeq target
regions. In summary, both kits targeted more than just
exon regions but they also did not have 100% coverage
of known exons.
We shifted the Illumina base quality scores (Phred +
64) to the Sanger scale (Phred + 33) [15] and performed
initial alignment to the NCBI human reference genome
(version 36 for SureSelect data and 37 for TrueSeq data)
using the program Burrows-Wheeler Aligner (BWA)
[16]. We then marked duplicates with Picard [17] and
carried out regional realignment and quality score recali-
bration using Genome Analysis Toolkit (GATK) [18].
For variant calling, we only used reads with a mapping
quality score (MAPQ) ≥20 (i.e., ≤1% probability of being
wrong) and bases with base quality score (BQ) ≥20. We
used GATK's Unified Genotyper to call SNPs simultan-
eously on all SureSelect samples and then on all True-
Seq samples.
Our SNP filtering criteria were determined through
the following steps: 1) Plot Ti/Tv ratio versus genotype
quality score (GQ), depth, allelic balance, BQ, and
MAPQ for all SNPs and separately for SNPs in dbSNP
and novel SNPs. 2) Draw the above plots only for SNPs
inside target regions. 3) Calculate overall and heterozy-
gote consistency rates with GWAS data for SNPs over-
lapping both platforms, filtered by GQ, depth, BQ, and
MAPQ. 4) Identify the best filtering criteria that resulted
in both high genotype consistency rates and Ti/Tv ratios
close to expected values (see next section for details).
We found that the two most effective factors affecting
sequencing data genotype quality were GQ and depth,
and used both GQ ≥ 20 and depth ≥ 5 as genotype filters
throughout the study unless otherwise specified.
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study of the 1000 Genomes Project, which designed a
capture assay for the exons of 1000 genes (8,496 target
regions, 1.4 million bases, average length 169 bp) [8].
Currently, only SNP calls for positions inside the target
regions were reported. We selected subjects that were
also in the HapMap II so that we could evaluate SNP
call quality of sequencing data by comparing them with
HapMap genotypes. We focused on Caucasian subjects
as a complement to our Asian samples. Two sequencing
platforms, Illumina and 454 Life Sciences, were used for
those subjects. We focused on the Illumina platform be-
cause it used shorter DNA fragments, which tend to
overlap more with the typically short target regions. We
selected subjects with paired-end data and no flags of
“failing” or “withdrawn.” Among those who qualified the
above criteria, we selected two subjects from each se-
quencing center with the highest number of reads:
NA12043 and NA12144 from the Sanger Center (SC),
which used Nimblegen 385-K array hybridization
method; NA12249 and NA12716 from the Washington
University Genome Sequencing Center (WUGSC),
which used a biotinylated capture library generated by
PCR in the presence of biotinylated CTP from a pool of
190 bp synthesized oligos; and NA12154 and NA12005
from the Broad Institute (BI), which used RNA baits
transcribed in the presence of biotinylated UTP from
primers cleaved from an Agilent microarray. Subject
NA12005 had the third highest number of reads from
BI; the subject with the second highest number of reads,
NA12892, had a very high fraction of non-aligned reads
(~10% for one of its two FASTQ files in contrast to ~2%
for the other subjects). We downloaded the FASTQ files
that were used in the Pilot 3 study and performed the
same data processing procedure as that for our samples.
For estimation of genotype consistency rate, we down-
loaded the HapMap II genotype data for these subjects.
Data quality measurement
One measurement of quality for sequence-based SNP
calls is whether they can be validated using an alterna-
tive genotyping platform. We thus calculated genotype
consistency rate between sequence-based and Affymetrix
chip-based SNP calls [13] for SNPs overlapping the two
platforms for our subjects, and between sequence-based
SNP calls and HapMap genotypes for the subjects from
the 1000 Genomes Project. We calculated two types of
consistency rate: overall consistency and heterozygous
SNP consistency, which probably is more informative on
the true error rate. Heterozygote consistency rate was
computed as the number of heterozygous genotypes
consistent between SNP chip and sequencing divided by
the number of heterozygous genotypes on SNP chip that
had sequence-based calls with GQ ≥ 20. Furthermore, wecalculated Ti/Tv ratio as another measure of data qual-
ity. The Ti/Tv ratio is around 3.0 for SNPs inside exons
and about 2.0 elsewhere [19]; it also differs between syn-
onymous and non-synonymous SNPs [20]. Since the tar-
get regions of exome capture kits often cover more than
just exons, the Ti/Tv ratio for SNPs inside target regions
is between 2.0 and 3.0 with the value depending on the
fraction of exons inside target regions. We also com-
pared the Ti/Tv ratios between novel SNPs and the SNPs
reported in dbSNP.
For clarity of presentation, we classified bases into
three categories: inside a target region (denoted "inside
TR"), outside target regions but within 200 bp from the
nearest target region (denoted "outside ≤200 bp"), and
outside target regions with >200 bp distance from the
nearest target region (denoted "outside >200 bp"). The
choice of 200 bp was because the insert sizes of the data
we analyzed were mostly between 150 and 200; we also
used 100 bp as a threshold and similar patterns of
results were observed (data not shown). Reads were clas-
sified similarly: a read was "inside TR" if at least half of
its bases were inside a target region; similarly, a read was
"outside ≤ 200 bp" if at least half the bases were within
200 bp from the nearest target region. The length of a
read was determined after applying soft clips according
to its CIGAR string information in the BAM file [21].
We studied SNP quality and distribution in the three
categories defined above. Furthermore, we annotated
SNPs "outside> 200 bp" using the functional variant an-
notation tool ANNOVAR [22].
Results
Quality of SNP chip genotypes
The 22 breast cancer patients sequenced with the Agi-
lent SureSelect capture kit and the 6 samples sequenced
with the Illumina TrueSeq capture kit were part of 2776
patients that were genotyped using the Affymetrix SNP
6.0 array in a genome-wide association study; detailed
genotyping methods and stringent QC criteria were
described in Zheng et al. [13]. The original scan included
three quality control samples in each 96-well plate, and
the SNP calls showed a very high concordance rate
(mean 99.9%; median 100%) for the quality control sam-
ples. In addition, 742 SNPs were genotyped using alter-
native genotyping platforms for a subset of subjects, and
they also had a high concordance rate with genotypes
obtained from the SNP chip (mean 99.1%; median
99.8%). The SNP chip call rate for the 28 samples inves-
tigated here ranged from 97.83% to 99.99%.
Coverage and distribution of sequence data
Additional file 1: Table S1 contains detailed summaries
for the samples we studied. For the 22 samples
sequenced with the Agilent SureSelect capture kit, we
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reads per subject, with 45x median depth for the SureSe-
lect target regions. On average, 91.4% (88.4-93.8%) of
the reads were aligned to the human reference genome,
and 94.2% (92.6-95.5%) had insert size ≤ 500 among the
aligned reads. The six samples sequenced with the Illu-
mina TrueSeq capture kit had an average of 93.8 (range
91.3-98.0) million reads and achieved 48x median depth
for the TrueSeq target regions. On average, 96.2% (92.4-
99.1%) of the aligned reads had insert size ≤ 500. The six
samples sequenced by the 1000 Genomes Project had an
average of 67.9 (range 47.5-83.7) million reads and
achieved 59x median depth for their target regions. On
average, 98.6% (98.5-98.8%) of the aligned reads had in-
sert size ≤ 500.
For all three data sets, a significant amount of the reads
were more than 200 bases away from target regions
(Table 1; details in Additional file 1: Table S2). Among
the aligned reads with MAPQ ≥20, our SureSelect data
had an average of 56.1% reads (range 53.6-58.8%) "inside
TR", 10.4% (9.4-13.4%) "outside ≤200 bp", and 33.5%
(30.4-36.0%) "outside >200 bp". Our TrueSeq data had
an average of 46.3% reads (range 45.7-46.7%) inside tar-
get regions, 21.7% (21.4-21.9%) "outside ≤ 200 bp", and
32.0% (31.5-32.9%) "outside >200 bp". The six samples
from the 1000 Genomes Project had an even higher frac-
tion of reads outside target regions: 28.7% (range 26.8-
29.6%) "inside TR", 18.6% (8.9-24.9%) "outside ≤ 200 bp",
and 52.7% (43.0-64.3%) "outside >200 bp".
As expected, the depth of coverage was the highest for
"inside TR" and lowest for "outside >200 bp". For bases
around the boundaries of target regions, the average
depth follows a clear decreasing pattern as the position
moves away from target regions (Figure 1). This is true
for all three data sets we analyzed. However, when we
focused on reads with MAPQ ≥ 20, the distributions of
MAPQ and BQ scores were similar across all three cat-
egories of regions we defined (Figure 2). This suggestsTable 1 Distribution of reads aligned to the human reference
percentage
Overall Inside TR
SureSelect (n = 22) # Reads # Reads %
Before filter 63.4 (9.6) 34.3 (4.9) 54.1
After filter 57.2 (8.6) 32.0 (4.5) 56.1
TrueSeq (n = 6)
Before filter 86.2 (2.5) 37.0 (0.7) 42.9
After filter 75.1 (2.1) 34.8 (0.7) 46.3
1000 G (n = 6)
Before filter 33.9 (8.1) 7.6 (1.2) 22.3
After filter 25.6 (3.8) 7.3 (1.1) 28.7
The filter was MAPQ≥ 20.that after filtering most data outside target regions were
as good as those inside target regions. The zigzag pat-
tern in Figure 2 panels (b), (e), and (h) was an artifact of
the MAPQ computation algorithm in BWA, which was
used to align all the data investigated here.
In our SureSelect data, on average, 97.0% (range 96.5-
97.2%) of the sites "inside TR" and 43.8% (38.0-47.7%) of
the sites "outside ≤ 200 bp" were covered with at least
one read. Of the nearly 3 billion sites "outside >200 bp",
an average of 25.5% (14.1-26.1%) were covered with at
least one read. Among the sites that had ≥5x depth of
coverage, a significant portion still fell outside target
regions (Figure 3a): 25.7 million (28.9%) were outside
≤200 bp and 28.2 million (31.7%) were outside >200 bp.
The results were similar for our TrueSeq data and the
data from the 1000 Genomes Project (Figure 3b,c).
We also examined the GC content of the sequence data
we collected. For our SureSelect target regions, the GC
content for "inside TR" was 50.6% and dropped to 42.0%
for the "outside ≤ 200 bp" regions. For bases "outside
> 200 bp" with depth of coverage≥ 10, the GC content
was around 46% (Table 2). Similar patterns were observed
for the data sequenced with the Illumina TrueSeq capture
kit and by the 1000 Genomes Project (Table 2). The
higher GC content inside target regions is a reflection of
the known higher GC content of coding regions.
SNPs inside and outside target regions
We used GQ ≥ 20 and depth ≥ 5 as the thresholds for
SNP filtering. For our SureSelect data, we identified
65,231 SNPs inside the target regions, with Ti/Tv ratio
2.81 and heterozygote consistency rate 99.2%. In
addition, a total of 84,049 high quality SNPs were identi-
fied outside the target regions (Figure 4a,b,c). For "out-
side ≤ 200 bp" regions, at depth ≥ 5, we observed an
average of 44,854 SNPs per subject, with Ti/Tv ratio 2.26;
77.1% of the SNPs were in dbSNP131. The overall
consistency rate with array-based SNP calls was 99.5% ongenome: average (standard deviation) in millions, and
Outside≤ 200 bp Outside >200 bp
# Reads % # Reads %
6.4 (1.2) 10.1 22.7 (3.9) 35.8
6.0 (1.1) 10.4 19.2 (3.3) 33.5
17.1 (0.3) 19.8 32.1 (1.3) 37.2
16.3 (0.3) 21.7 24.0 (1.1) 32.0
4.7 (1.7) 14.0 21.6 (8.4) 63.7
4.7 (1.7) 18.6 13.6 (3.6) 52.7
Figure 1 Average depth around boundaries of target regions (1-50 bp inside and 1-200 bp outside boundaries). Negative distance
means inside a target region, and positive distance means outside a target region.
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>200 bp" regions, at depth≥ 5, we observed on average
39,195 SNPs per subject (Ti/Tv ratio 1.83; 68.3% in
dbSNP131; overall consistency rate 99.2%; heterozygote
consistency rate 98.9%). For "outside >200 bp" regions, the
Ti/Tv ratio increased as depth increased; at depth≥ 20, we
observed 15,539 SNPs with Ti/Tv ratio 2.11 and >99%
consistency with array-based SNP calls. The detailed SNP
numbers and Ti/Tv ratio can be found in Additional file 1:
Table S3–S8. The distribution of coverage for SNPs identi-
fied outside capture regions can be seen in Table 3.
For the six samples sequenced with the Illumina True-
Seq capture kit, we identified 95,818 SNPs inside target
regions (Ti/Tv ratio 2.30; heterozygote consistency rate
99.6%) and a similar pattern of high quality SNPs out-
side the target regions (Figure 4d,e,f ). For outside ≤
200 bp regions, at depth ≥ 5, we observed an average
of 117,866 SNPs per subject (Ti/Tv ratio 2.01; 87.4% in
dbSNP132; overall consistency rate 99.6%; heterozygote
consistency rate 99.6%). For outside >200 bp regions, at
depth ≥ 5, we observed an average of 104,305 SNPs persubject (Ti/Tv ratio 1.89; 77.3% in dbSNP132; overall
consistency rate 99.2%; heterozygote consistency rate
99.1%).
For the six samples sequenced by the 1000 Genomes
Project, we identified 1,548 SNPs inside their target regions
(Ti/Tv ratio 3.23; heterozygote consistency rate 99.3%) and
many high quality SNPs outside the target regions (Figure
4g,h,i). For outside≤ 200 bp regions, at depth≥ 5, we
observed an average of 3,011 SNPs per subject (Ti/Tv ratio
2.23; 92.5% in dbSNP131; overall consistency rate 98.6%;
heterozygote consistency rate 99.6%). For outside >200 bp,
at depth≥ 5, we observed an average of 4,128 SNPs per
subject (Ti/Tv ratio 1.80; 85.3% in dbSNP131; overall
consistency rate 97.2%; heterozygote consistency rate
98.7%). At depth≥ 20, we observed 1,883 SNPs with Ti/Tv
ratio 1.96 and >98% consistency with HapMap data.
We used ANNOVAR to annotate the SNPs identified
more than 200 bp away from target regions. The charac-
teristics of those SNPs are summarized in Table 4. For
sites with average depth ≥ 5 in our SureSelect data, we
observed 6,194 SNPs in introns, 35 within 2 bp of a
Figure 2 Distributions of depth, mapping quality score, and base quality score for “Inside TR”, “Outside ≤200 bp”, and
“Outside> 200 bp”.
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and 33,569 intergenic. We were also able to observe
many exonic SNPs that were outside the target regions
of the SureSelect or TrueSeq capture kit used for gener-
ating our data, including 981 non-synonymous SNPs
and 25 stop-gain and 4 stop-loss mutations. These po-
tentially functional SNPs could be missed if the investi-
gator would only look at results inside target regions.
We also summarized the results for sites with average
depth ≥10, and repeated this procedure for our TrueSeq
data and the data generated by the 1000 Genomes Pro-
ject (Table 4).Discussion
Our samples were blood samples from breast cancer
patients. Though they were not a random sample, we ex-
pect this to have little impact on the generalizability of
the phenomena we observed. We did not evaluate any
data generated by sequencers from 454 Life Sciences or
Applied Biosystems. However, we expect similar results
for these platforms because the SureSelect whole exome
capture kit we used was designed to be compatible with
all three major platforms of sequencing technology.
We examined if SNP quality could be influenced by arti-
facts. One artifact of exome capturing is strand imbalance;
Figure 3 Distribution of sites with a minimum depth of 5 to 10.
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be heavily uneven at many positions, especially those close
to the boundaries of target regions. This phenomenon
exists for positions both inside and outside target regions,
although it is more extreme outside target regions. In ex-
treme situations, all reads can be on the same strandTable 2 GC content (base pairs in millions)
Inisde TR Outside≤ 200 bp
SureSelecta total BP 37.8 61.0
(n = 22) GC 19.1 25.6
GC% 50.6% 42.0%
TrueSeqb total BP 62.1 76.9
(n = 6) GC 30.4 32.5
GC% 49.0% 42.30%
1000 Gc total BP 1.4 3.3
(n = 6) GC 0.7 1.4
GC% 51.6% 41.6%
a Based on hg18 and Agilent SureSelect v1.
b Based on hg19 and Illumina TrueSeq.
c Based on hg18 and NimbleGen 1.4 M cap kit.(examples in Additional file 1: Table S9). Using our Agi-
lent SureSelect data, we selected all positions where the
depth was ≥5, all reads were on one strand, and GWAS
genotypes were available; 46,069 positions only had for-
ward reads, and 43,145 positions only had reverse reads.
We computed genotype consistency rates with GWASOutside> 200 bp










Figure 4 Average SNP count per sample, heterozygote consistency, and Ti/Tv ratio.
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consistency rates were above 98.5%. Thus, the strand im-
balance had little effect on genotype quality.
Another artifact we observed with exome sequencing is
that some regions far away from target regions had abnor-
mally high coverage, with depth in the hundreds. We sus-
pected that this high coverage might be a result of strong
homology between intergenic regions and exome regions,
causing nonspecific binding during the capture process.
Using our Agilent SureSelect data we picked 10 regions with
very high depth (Additional file10: Table S10) and examined
them against the pseudo gene lists from Yale and UCSC(www.pseugenes.com). Only 2 regions overlapped with
pseudo genes. We also BLASTed [17] these 10 intervals
against the SureSelect target regions and found that most of
these intervals had strong homology with sequences inside
the target regions (Additional file 1: Table S10). Our analysis
results on GC content also suggest that many of the high
depth regions "outside> 200 bp" have strong homology with
coding regions and thus a higher GC content than introns.
Further study is needed to understand the full extent of se-
quence homology in the human genome.
In addition to SNPs, we found many indels outside target
regions that had high quality scores. For our data sequenced
Table 3 Distributions of depth for SNPs outside capture regions that had GQ≥ 20 and depth≥ 5
Depth SureSelect TrueSeq 1000 G
≤ 200 bp > 200 bp ≤ 200 bp > 200 bp ≤ 200 bp > 200 bp
5 1156 3463 1225 3963 38 194
6 1000 1681 1278 2950 46 142
7 4036 3630 3200 4702 135 290
8 3483 2570 4005 4582 123 246
9 3040 2020 4222 3995 103 199
10 2647 1658 4231 3447 98 174
11 2349 1420 4261 2972 95 160
12 2099 1251 4223 2628 85 142
13 1866 1096 4188 2366 91 122
14 1694 995 4110 2136 84 115
15 1535 891 4072 1906 84 105
16 1376 823 3949 1749 71 101
17 1270 766 3887 1649 67 91
18 1159 721 3743 1490 67 84
19 1072 672 3654 1421 64 83
≥ 20 15074 15539 63620 62350 1762 1884
The numbers are average numbers of SNPs over the samples from the same capture assay.
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Score (reported by GATK's Unified Genotyper)≥1000, 2,383
indels were detected by GATK's Unified Genotyper inside
the target regions, 5,344 were outside≤200 bp, and 4,158
were outside> 200 bp. The numbers were 7,211, 9,456, and
7,426 for the six TrueSeq samples, and 10, 273, and 207 for
the six samples sequenced by the 1000 Genomes Project.
Systematic validation of these indel calls would take a signifi-
cant amount of effort and is beyond the scope of this paper.
The amount of information outside target regions depends
on capture efficiency, which varies across different capturing
technologies. With Agilent’s SureSelect v1 capturing kit, only
55% of the reads in our data were aligned within target
regions; it was about 50% for Illumina’s TrueSeq capture kit.




SureSelect ≥ 5 6194 35 4873
(n = 22) ≥ 10 4297 34 3790
TrueSeq ≥ 5 29372 8 7537
(n = 6) ≥ 10 16252 7 10153
1000 G ≥ 5 2619 11 309
(n = 6) ≥ 10 1352 8 168
a Variant is within 2-bp of a splicing junction.
b Variant overlaps a transcript without coding annotation in the gene definition.the newer kits. But even the most current capture kit today
can only claim to have around 80% capture efficiency [23],
while the real capture efficiency is probably lower in practice.
We have shown little quality deterioration outside target
regions after filtering. Thus for exome and targeted sequen-
cing data, instead of inefficiently limiting ourselves to var-
iants inside target regions, we should also analyze data in
any regions with high-quality SNP calls.
Furthermore, exome sequencing has also been used
with non-human subjects. Regardless of the organism
being sequenced, our findings about data outside target
regions should apply. By including SNPs outside target
regions, the genomic coverage is effectively improved
and the chance of identifying quantitative trait loci is
increased.Intergenic Exonic
Non-synonymous Stopgain Stoploss
33569 981 25 4
21713 792 17 3
74431 211 4 0
60889 199 4 0
1951 307 6 1
1183 213 5 1
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We studied the quality of SNP calls for positions outside
target regions using our whole exome sequencing data
and the 1000 Genomes Project Pilot 3 data. These data-
sets were generated using five different capture kits and
three different sets of target regions. The sequencing
was also performed at five different facilities. Despite
these differences, we observed reliable genotypes for
many SNPs outside target regions, some far outside tar-
get regions, in all datasets. By analyzing all available se-
quencing data and applying stringent filtering criteria,
we more than doubled the number of high-quality SNP
calls in comparison to what we would have if we had
just focused on target regions. Given the amount of sig-
nificant discovery researchers have made in the noncod-
ing regions, these extra SNPs residing outside target
regions should not be ignored in data analysis, especially
given the fact that sequencing is still relatively expensive.
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